A5040861340- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Economic and Financial Impacts of Cancer
- Liver Disease Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
Orenburg Regional Clinical Oncology Center
2022-2025
State Healthcare Institution "Regional Clinical Oncological Dispensary"
2024
The combination of lenvatinib and pembrolizumab (Len + Pembro) demonstrated significant efficacy in the phase 3 CLEAR study for metastatic renal cell carcinoma (RCC). However, poor-risk patients represented only a small proportion trial population. This multicenter retrospective cohort assessed real-world safety Len Pembro with clear-cell RCC intermediate or poor International Metastatic Database Consortium risk. Outcomes included objective response rate (ORR), progression-free survival...
Aim To evaluate the safety and toxicity of lenvatinib with pembrolizumab in unselected patients advanced renal cell carcinoma (RCC).
 Materials methods. The Russian phase IV observational study included 151 RCC who received a standard dose regimen 36 clinical centers Federation. Most were diagnosed clear (n=145, 96.0%), synchronous (n=77,51.0%) metastasesof more than one location (n=111,73.5%), removed primary tumor (n=98, 64.9%) classified into intermediate poor IMDC prognostic groups...
Objective: to re-evaluate the efficacy and safety of lenvatinib with pembrolizumab in unselected Russian renal cell carcinoma (RCC) patients, included phase IV study, a median follow-up extended 17.1 months. The primary end point was progression-free survival (PFS), secondary points were overall (OS), objective response rate (ORR) duration (DOR), disease control (DCR) its duration, as well safety. Materials methods. study medical data 165 patients verified advanced RCC who received 36...
Aim. To determine lenvatinib treatment outcomes in patients with advanced unresectable hepatocellular carcinoma (uHCC) real clinical practice. Patients and methods. A multicenter retrospective observational study included 58 a confirmed uHCC diagnosis receiving lenvatinib. At baseline, ECOG, Child-Pugh BCLC scores were assessed. The objective response rate (ORR), disease control (DCR), median overall survival (OS) progression-free (PFS) rates In addition, adverse effects (AE) during...